SCHEMBL487145

SCHEMBL487145

CC1=NN(c2nc(-c3ccc(Cl)cc3)cs2)C(=O)C1C

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.74
MAPK1 P28482 5/20 0.74
RAB9A P51151 5/20 0.74
ALDH1A1 P00352 4/20 0.74
NPC1 O15118 4/20 0.74
SMN1; SMN2 Q16637 4/20 0.74
L3MBTL1 Q9Y468 3/20 0.74
GAA P10253 3/20 0.74
MEN1 O00255 9/20 0.61
KMT2A Q03164 9/20 0.61
TDP1 Q9NUW8 4/20 0.61
POLB P06746 3/20 0.61
BLM P54132 2/20 0.61
KDM4E B2RXH2 1/20 0.61
ALOX12 P18054 1/20 0.61
HTT P42858 1/20 0.61
SIRT5 Q9NXA8 6/20 0.56
AR P10275 1/20 0.50
XBP1 P17861 1/20 0.49
CTDSP1 Q9GZU7 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23192329 0.78 MAPT (0.52) MAPTMAPK1RAB9AALDH1A1NPC1
SCHEMBL22952588 0.73 MAPT (0.50) MAPTMAPK1RAB9AALDH1A1NPC1
SCHEMBL16273457 0.71 RAB9A (0.76) MAPTMAPK1RAB9AALDH1A1NPC1
SCHEMBL14678567 0.69 AR (0.62) MAPTMAPK1RAB9ANPC1SMN1; SMN2
SCHEMBL6628766 0.69 AR (0.58) MAPTMAPK1RAB9ANPC1SMN1; SMN2
SCHEMBL28911465 0.66 SIRT5 (1.00) SIRT5G6PD
SCHEMBL16273452 0.66 SIRT5 (0.56) MAPTMAPK1RAB9ANPC1L3MBTL1
SCHEMBL16273555 0.66 MAPT (1.00) MAPTMAPK1RAB9AALDH1A1NPC1
SCHEMBL2405184 0.66 RAB9A (0.71) MAPTRAB9AALDH1A1NPC1SMN1; SMN2
SCHEMBL8799905 0.66 AR (0.62) MAPTMAPK1RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411526-A2 GANGLIOSIDE BIOSYNTHESIS MODULATORS Zacharon Pharmaceuticals, Inc. (US) 2012-02-01 EP disclosed
US-20100248365-A1 GANGLIOSIDE BIOSYNTHESIS MODULATORS ZACHARON PHARMACEUTICALS, INC. (US) 2010-09-30 US disclosed
US-20100248365-A1 GANGLIOSIDE BIOSYNTHESIS MODULATORS ZACHARON PHARMACEUTICALS, INC. (US) 2010-09-30 US disclosed
WO-2010111711-A2 GANGLIOSIDE BIOSYNTHESIS MODULATORS ZACHARON PHARMACEUTICALS, INC. (US) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100248365-A1 GANGLIOSIDE BIOSYNTHESIS MODULATORS UGCG, MAGT1, STT3B MAPT 4120/4885MAPK1 2673/4885RAB9A 1124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.